Clinical Trial Update: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) [Phase 3]

View source ↗

Summary

EMPEROR-Preserved is a Phase 3 trial evaluating empagliflozin in patients with heart failure with preserved ejection fraction; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2022-06-06